No abstract

Background Early life conditions are associated with lung function and the development of respiratory and non-respiratory illnesses. The relationship with birthweight (BW) is however conflicting. We examined associations of BW with lung function and respiratory diseases within the GEIRD (Gene-Environment Interaction in Respiratory Diseases) study. Methods GEIRD is an Italian multi-centre, multi-case control study of people aged 20-84 from the general population conducted from 2008 to 2014. The study included cases of COPD, asthma, allergic rhinitis and controls. Multinomial logistic regression was performed with case/control status (control/COPD/asthma/allergic rhinitis) as response variable, and BW as main determinant adjusting for sex, age and smoking status. Results Of 2,287 reporting BW, 6.4 % (n = 147) had low BW (<2500 gr), and this proportion was greater in women than men (7.8% vs. 5.1%; p = 0.006). Lung volumes were significantly lower in individuals with low than normal BW. Median FEV1 was 3.01 L (p25-p75=2.60-3.45 L) versus 3.16 L (2.65-3.86 L) (p = 0.019) and median FVC was 3.68 L (3.19-4.34 L) versus 3.91 (3.34-4.81 L) (p = 0.003). However, FEV1 and FVC were not affected by BW when expressed as percent predicted. Of note, both men and women with low BW were shorter than those with normal BW (mean±SD: 160.2±5.5 vs. 162.6±6.5 cm in women, p = 0.009; 172.4±6.1 vs. 174.8±7.2 cm in men, p < 0.001). FEV1/FVC expressed as absolute ratio or as percent predicted, was not affected by BW. In multinomial analysis, BW was not associated with respiratory diseases in adulthood. However, those with low BW had a higher risk of self-reported hospitalisation for lung disease before age 2 (10.3% vs. 4.1%) and severe respiratory infection before age 5 (16.9% vs. 8.8%) (p = 0.003). Conclusions BW was not associated with lung function in adulthood, when controlling for sex and height. Low BW was a risk factor for respiratory diseases in childhood, not in adulthood. Key messages • Low birthweight was associated with respiratory diseases in childhood but not in adulthood. • Although spirometrically-assessed lung volumes were lower in adults with low birthweight, this is likely explained by associations of low birthweight with sex and height.

Early life conditions are associated with lung function and the development of respiratory and non-respiratory illnesses. The relationship with birthweight (BW,) however, is conflicting. We examined associations of self-reported BW with lung function and the development of respiratory and also non-respiratory diseases within the GEIRD (Gene–Environment Interaction in Respiratory Diseases) project, an Italian multi-centre, multi-case control study involving cases of COPD, asthma, allergic rhinitis and controls. Multinomial logistic regression was performed with case/control status as response variable; BW as main determinant; and sex, age and smoking status were adjusted for. Of the 2287 participants reporting BW, 6.4% (n = 147) had low BW (<2500 g), and this proportion was greater in women than men (7.8% vs. 5.1%; p = 0.006). Both men and women with low BW were shorter than those with normal BW (mean ± SD: 160.2 ± 5.5 vs. 162.6 ± 6.5 cm in women, p = 0.009; 172.4 ± 6.1 vs. 174.8 ± 7.2 cm in men, p < 0.001). Although FEV1 and FVC were reduced in individuals with low BW, this was explained by associations with sex and height. In multivariable analysis, BW was not associated with respiratory diseases in adulthood. However, those with low BW had a higher risk of self-reported hospitalisation for lung disease before the age of two (10.3% vs. 4.1%; p < 0.001), severe respiratory infection before the age of five (16.9% vs. 8.8%; p = 0.001) and hypertension in adulthood (29.9% vs. 23.7%; p = 0.001); however, they had a lower risk of arrhythmia (2.7% vs. 5.8%; p = 0.027).

e24207 Background: Measures adopted to contain COVID-19 may impact cancer pts' psychological well-being and clinical status. We assessed the psychological status and attitude towards COVID-19 vaccination in adult cancer pts who accepted vaccination at the University and Hospital Trust of Verona and Camposampiero Hospital in the Veneto region. Methods: A self-reported questionnaire was administered to pts undergoing the first and second dose of COVID-19 vaccination in the context of the vaccination campaign promoted by the Veneto Oncology Network (Rete Oncologica Veneta - ROV) between March and May 2021. Overall, 27 items were investigated: i) demographics/clinical characteristics; ii) psychological status (Hospital Anxiety and Depression Scale - HADS - and Distress Thermometer - DT); iii) awareness about infection risks, interference with anticancer treatments, and vaccine side effects. Results: Overall, only 2.5% of the invited active oncological population refused COVID-19 vaccination. Data collected in both Verona and Camposampiero (1089 and 286 respondents, respectively) demonstrated borderline and clinical levels of anxiety in 14% and 10% of pts, borderline and clinical levels of depression in 14% and 8% of pts; and moderate and severe distress levels in 33% and 9% of pts, respectively. No significant differences between the two sites and between the first and second dose were observed, with the exception of significantly lower levels of distress at the time of the second dose administration at the Camposampiero site. In the Verona cohort, clinical anxiety was significantly more frequent in breast cancer and rare tumor pts (17.5% and 21.4%, respectively; p= 0.005); no significant associations were found for depression and distress. Overall, there was high confidence that vaccination would reduce the risk of contracting COVID-19 (70%), which would make pts feel less worried about contracting the infection (60%); among pts with borderline and clinical depression levels, there was less confidence that vaccination would "make [them] feel less worried to contract COVID-19" ["Not at all" or "Only a little" in 16.2% and 20% of pts with borderline and clinical depression levels, respectively, as opposed to 6.6% among pts with normal depression levels (p = 0.005)]. Fear that vaccine-related side effects would interfere with anticancer treatment and/or global health status was low (10% and 9% for items 3 and 4, respectively) and significantly associated with baseline psychological status at multivariate analysis. Similar results were obtained in the Camposampiero cohort. Conclusions: During the COVID-19 vaccination campaign, adult cancer pts demonstrated high levels of confidence towards vaccination; baseline psychological status was the only significant predictor of reduced confidence.